The purpose of the Molecular Resource Core (MRC) is to provide support for the analysis of genes and gene products that are relevant to the pathogenesis of arthritis. It will support studies of immune-mediated arthritis in both humans and mice. The MRC will take a multifaceted approach in that it will develop new assays and procedures, be a source of well-characterized Collagen, provide analysis of samples under standardized conditions with stringent quality control, and be a technical and educational resource. MRC facilities will isolate and purify collagen and peptides. This protein family has many unique characteristics that make it difficult or impossible to obtain reliably from commercial sources. The MRC will use state of the art equipment for molecular analyses to aid in the development and application of the most advanced molecular techniques to the study of rheumatic disease. It will perform highly sensitive determination of mRNA levels by quantitative real time polymerase chain reaction, including assisting investigators in the design of appropriate oligonucleotide primers and probe sets an. d will provide a standardized service for sample amplification, data collection and analysis. The MRC will aid both new and established investigators in the use of DNA microarray technology to discover new factors and genetic interactions that affect pathogenesis and modulation of disease. Since many rheumatic diseases are closely linked to particular MHC genes, it will provide HLA genotype determination to identify those haplotypes relative to disease with the capacity to perform fine specificity analysis down to the DNA sequence level. The availability of these services should facilitate research in rheumatic diseases for both clinical and basic scientists at the University of Tennessee, HSC.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR047379-02
Application #
6663357
Study Section
Special Emphasis Panel (ZAR1)
Project Start
2002-09-01
Project End
2003-08-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Type
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Hasty, Karen A; Cho, Hongsik (2016) Stem Cell Considerations for the Clinician. Phys Med Rehabil Clin N Am 27:855-870
Qian, Zhaohui; Latham, Kary A; Whittington, Karen B et al. (2013) Engineered regulatory T cells coexpressing MHC class II:peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis. J Immunol 190:5382-91
Qian, Zhaohui; Latham, Kary A; Whittington, Karen B et al. (2010) An autoantigen-specific, highly restricted T cell repertoire infiltrates the arthritic joints of mice in an HLA-DR1 humanized mouse model of autoimmune arthritis. J Immunol 185:110-8
Xing, Zhiqing; Schwab, Luciana P; Alley, Carie F et al. (2008) Titanium particles that have undergone phagocytosis by macrophages lose the ability to activate other macrophages. J Biomed Mater Res B Appl Biomater 85:37-41
Ye, Zhaoyang; Houssein, Houssam S Hajj; Mahato, Ram I (2007) Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides 17:349-404
Xing, Zhiqing; Hasty, Karen A; Smith, Richard A (2007) Administration of pamidronate alters bone-titanium attachment in the presence of endotoxin-coated polyethylene particles. J Biomed Mater Res B Appl Biomater 83:354-8
Yi, Ae-Kyung; Yoon, Hyunsook; Park, Jeoung-Eun et al. (2006) CpG DNA-mediated induction of acute liver injury in D-galactosamine-sensitized mice: the mitochondrial apoptotic pathway-dependent death of hepatocytes. J Biol Chem 281:15001-12
Rosloniec, Edward F; Brandstetter, Tilmann; Leyer, Sigmar et al. (2006) Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models. J Autoimmun 27:182-95
Carbone, L D; Warrington, K J; Barrow, K D et al. (2006) Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol 146:371-80
Rosloniec, Edward F; Ivey 3rd, Robert A; Whittington, Karen B et al. (2006) Crystallographic structure of a rheumatoid arthritis MHC susceptibility allele, HLA-DR1 (DRB1*0101), complexed with the immunodominant determinant of human type II collagen. J Immunol 177:3884-92

Showing the most recent 10 out of 24 publications